Intersect ENT Inc. (XENT) - Product Pipeline Analysis, 2016 Update

Report code: GDME47900PD

Publisher: GlobalData

Formats: PDF

Published: June 29, 2016

Number of pages: 31

Intersect ENT Inc. (Intersect), formerly Sinexus, Inc. is a medical equipment company that offers chronic sinusitis solutions. The company offers steroid releasing implants and mini steroid implants. Its products are used in chronic sinusitis treatment such as facial pain or pressure, nasal congestion or obstruction, loss of smell or taste, headache, discolored nasal discharge, loss of sleep or fatigue and depression. Intersect provides treatment through medical therapy and sinus surgery. Intersect has developed the propel steroid-releasing implant. The company distributes its products in domestic and overseas markets. Intersect is headquartered in Menlo Park, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Intersect ENT Inc.

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reason To Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Intersect ENT Inc. Company Snapshot 6

Intersect ENT Inc. Company Overview 6

Intersect ENT Inc. Pipeline Products and Clinical Trials Overview 7

Intersect ENT Inc. – Pipeline Analysis Overview 9

Key Facts 9

Intersect ENT Inc. - Major Products and Services 10

Intersect ENT Inc. Pipeline Products by Development Stage 11

Intersect ENT Inc. Clinical Trials by Trial Status 13

Intersect ENT Inc. Pipeline Products Overview 14

NOVA - Frontal Indication 14

NOVA - Frontal Indication Product Overview 14

NOVA - Frontal Indication Clinical Trial 15

NOVA- Maxillary Indication 16

NOVA- Maxillary Indication Product Overview 16

Propel Implant - Frontal Indication 17

Propel Implant - Frontal Indication Product Overview 17

Resolve- Ethmoid Sinus 18

Resolve- Ethmoid Sinus Product Overview 18

Steroid-Releasing S8 Sinus Implant 19

Steroid-Releasing S8 Sinus Implant Product Overview 19

Steroid-Releasing S8 Sinus Implant Clinical Trial 20

Intersect ENT Inc. - Key Competitors 21

Intersect ENT Inc. - Key Employees 22

Intersect ENT Inc. - Locations And Subsidiaries 23

Head Office 23

Recent Developments 24

Intersect ENT Inc., Recent Developments 24

Jun 01, 2016: Intersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis 24

May 16, 2016: Intersect ENT Announces Positive Clinical Results From Pivotal Study of Newest Steroid Releasing Sinus Implant 24

May 05, 2016: Intersect ENT Reports First Quarter 2016 Results 25

Mar 23, 2016: Intersect ENT Announces FDA Approval Of Additional Indication For PROPEL Mini Sinus Implant 26

Feb 23, 2016: Intersect ENT Reports Fourth Quarter and Year 2015 Results 27

Feb 22, 2016: Intersect ENT Appoints David Lehman General Counsel 28

Jan 29, 2016: Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany 28

Jan 11, 2016: Intersect ENT Reports Preliminary Q4 and Year 2015 Revenue 28

Nov 10, 2015: Intersect ENT Announces Data Further Demonstrating Health Economic Value of PROPEL Steroid Releasing Implants 29

Nov 04, 2015: Intersect ENT Reports Third Quarter 2015 Results 29

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31

List of Tables

List of Tables

Intersect ENT Inc. Pipeline Products and Clinical Trials Overview 7

Intersect ENT Inc. Pipeline Products by Equipment Type 7

Intersect ENT Inc. Pipeline Products by Indication 8

Intersect ENT Inc. Clinical Trials by Trial Status 8

Intersect ENT Inc., Key Facts 9

Intersect ENT Inc., Major Products and Services 10

Intersect ENT Inc. Number of Pipeline Products by Development Stage 11

Intersect ENT Inc. Pipeline Products Summary by Development Stage 12

Intersect ENT Inc. Clinical Trials by Trial Status 13

Intersect ENT Inc. Clinical Trials Summary 13

NOVA - Frontal Indication - Product Status 14

NOVA - Frontal Indication - Product Description 14

NOVA - Frontal Indication - Pivotal Study to Evaluate the NOVA Sinus Implant 15

NOVA- Maxillary Indication - Product Status 16

NOVA- Maxillary Indication - Product Description 16

Propel Implant - Frontal Indication - Product Status 17

Propel Implant - Frontal Indication - Product Description 17

Resolve- Ethmoid Sinus - Product Status 18

Resolve- Ethmoid Sinus - Product Description 18

Steroid-Releasing S8 Sinus Implant - Product Status 19

Steroid-Releasing S8 Sinus Implant - Product Description 19

Steroid-Releasing S8 Sinus Implant - A Clinical Evaluation of the Safety and Efficacy of the Steroid-Releasing S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Sinus Obstruction (RESOLVE II) 20

Intersect ENT Inc., Key Employees 22

List of Figures

List of Figures

Intersect ENT Inc. Pipeline Products by Equipment Type 8

Intersect ENT Inc. Pipeline Products by Development Stage 11

Intersect ENT Inc. Clinical Trials by Trial Status 13

Save time and money with a subscription

Require regular access to company intelligence? Why not consider a cost-effective subscription platform and gain access to 250,000+ reports?

To find out more, click here or call +91 (0)40 4961 4567.

Single User License
Electronic PDF copy delivered via email.

Report can be used by individual purchaser only.

$750

Site License
Electronic PDF copy delivered via email.

Report can be shared by unlimited users within one corporate location,
e.g. a regional office.

$1500

Global License
Electronic PDF copy delivered via email.

Report can be shared globally by unlimited users within the purchasing corporation
e.g. all employees of a single company.

$2250

TOP